GenSight Biologics and National Hospital to publish GS030 phase 1/2 results in NEJM

GenSight Biologics said NEJM published PIONEER Phase 1/2 results for GS030 in late-stage retinitis pigmentosa, reporting primary safety findings and exploratory visual function assessments. GS030 has not received marketing authorization.Material DetailsContext by AI AnalystThis is early-stage valid…